Not provided
Not provided
Not provided
Not provided
This action is an internal decision that was not made because of any pending regulatory action for these products.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Multicenter, Randomized, Controlled Trial to Determine Safety and Efficacy of Pump Assisted Lung Protection (PALPâ„¢) for Low Flow Carbon Dioxide (CO2) Removal in Conjunction with Liberation from Mechanical Ventilation Compared to Mechanical Ventilation Alone in Patients with COPD Exacerbation and Respiratory Failure
Primary Study Objectives
• To evaluate the clinical effect of PALP™ in reducing the time on invasive ventilation in patients with an exacerbation of COPD requiring invasive mechanical ventilation.
Secondary Study Objectives
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mechanical ventilation (MV) | No Intervention | mechanical ventilation according to guidelines | |
| MV + ECCO2-R(PALP-Device/MaquetCP) | Experimental | MV according to the guidelines plus CO2-Removal with PALP |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CO2-Removal (PALP-Device/MaquetCP) | Device | extracorporeal circuit to remove CO2 out of the blood |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in time of mechanical ventilation | • To evaluate the clinical effect of PALP™ in reducing the time on invasive ventilation in patients with an exacerbation of COPD requiring invasive mechanical ventilation. | 720 hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Any end-stage medical conditions with expected survival <6 months
Tracheostomy
Unable to provide central venous access
Acute brain injury
Any legally authorized document(s) that may restrict aggressive medical management such as "Do Not Resuscitate," "Do Not Intubate," etc.
Risk of bleeding or clotting such as:
Screening platelet count of <75,000/mm3 or international normalized ratio (INR) >1.5 or activated partial thromboplastin time (aPTT) >1.5 times the upper limit of normal (ULN) range for their respective laboratory values
Any recognized contra indications to systemic anticoagulation therapy or use of heparin
Body mass index (BMI) >35
Any form of chronic hyperventilation not related to COPD
Hemodynamic instability or requiring significant vasopressor support
Cardiogenic or noncardiogenic pulmonary edema as the primary reason for respiratory failure
High risk cardiac conditions
Oxygen tension in arterial blood (PaO2) <50 mmHg via arterial blood gas (ABG) or any condition in which hypoxemia is a significant component of the respiratory failure
Any other medical cause for acute respiratory failure not directly related to a COPD exacerbation
Use of or treatment with an investigational drug, therapy, or device within 1 month (30 days) of baseline
Female patients who are pregnant or breastfeeding
Patients who are immuno-compromised
Current active malignancy or history of malignancy within the past 5 years
Patients in chronic dialysis
Patients requiring extra-corporeal life support (ECLS) as a bridge to transplant
Patients who, in the opinion of the investigator, would not be able to comply with the requirements of the study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marco V Ranieri, MD PhD | Investigational institution | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MAQUET Cardiopulmonary AG | Rastatt | 76437 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23952848 | Result | Abrams DC, Brenner K, Burkart KM, Agerstrand CL, Thomashow BM, Bacchetta M, Brodie D. Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013 Aug;10(4):307-14. doi: 10.1513/AnnalsATS.201301-021OC. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |